Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

BRIDGES

Financiado

Cerrado

Breast Cancer Risk after Diagnostic Gene Sequencing BRIDGES

Breast cancer affects more than 360,000 women per year in the EU and causes more than 90,000 deaths. Identification of women at high risk of the disease can lead to disease prevention through intensive screening, chemoprevention o... ver más

31/08/2021

Leiden University...

6M€

Presupuesto del proyecto: 6M€

Líder del proyecto

ACADEMISCH ZIEKENHUIS LEIDEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 19 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2021-08-31

PHC-05-2014: Health promotion and disease preven...

I+D

Cerrada hace 10 años

0% 96% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

19 Participantes

Leiden University Medical Ce...

895.00K€ | Lider

DOMINIO DE PINGUS

393.78K€ | Participante

UNIVERSITE LAVAL

51.25K€ | Participante

166.88K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

SAF2010-21165 ANALISIS GENOMICO DEL CANCER FAMILIAR MEDIANTE SECUENCIACION... 97K€ Cerrado

IHCAP Investigating Hereditary Cancer Predisposition a combined... 1M€ Cerrado

SAF2013-45836-R ANALISIS GENOMICO DEL CANCER HEREDITARIO 151K€ Cerrado

NGG Next Generation Genetics of Cancer Predisposition 2M€ Cerrado

RTI2018-098419-B-I00 LA RUTA ANEMIA DE FANCONI/BRCA: INVESTIGACION GENETICA Y TER... 315K€ Cerrado

COLONGEVA Implications of copy number variants of the genome in the et... 100K€ Cerrado

Duración del proyecto: 76 meses Fecha Inicio: 2015-04-07
Fecha Fin: 2021-08-31

Líder del proyecto

ACADEMISCH ZIEKENHUIS LEIDEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 6M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Breast cancer affects more than 360,000 women per year in the EU and causes more than 90,000 deaths. Identification of women at high risk of the disease can lead to disease prevention through intensive screening, chemoprevention or prophylactic surgery. Breast cancer risk is determined by a combination of genetic and lifestyle risk factors. The advent of next generation sequencing has opened up the opportunity for testing in many disease genes, and diagnostic gene panel testing is being introduced in many EU countries. However, the cancer risks associated with most variants in most genes are unknown. This leads to a major problem in appropriate counselling and management of women undergoing panel testing. In this project, we aim to build a knowledge base that will allow identification of women at high-risk of breast cancer, in particular through comprehensive evaluation of DNA variants in known and suspected breast cancer genes. We will exploit the huge resources established through the Breast Cancer Association Consortium (BCAC) and ENIGMA (Evidence-based Network for the Interpretation of Germline Mutant Alleles). We will expand the existing datasets by sequencing all known breast cancer susceptibility genes in 20,000 breast cancer cases and 20,000 controls from population-based studies, and 10,000 cases from multiple case families. Sequence data will be integrated with in-silico and functional data, with data on other known risk factors, to generate a comprehensive risk model that can provide personalised risk estimates. We will develop online tools to aid the interpretation of gene variants and provide risk estimates in a user-friendly format, to help genetic counsellors and patients worldwide to make informed clinical decisions. We will evaluate the acceptability and utility of comprehensive gene panel testing in the clinical genetics context.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores